Detalles de la búsqueda
1.
Appendiceal Metastasis of Breast Cancer: A Case Report and a Literature Review.
Cureus;
16(4): e57929, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38725791
2.
Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.
Breast Cancer;
31(2): 283-294, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175422
3.
Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
Breast Cancer;
31(2): 234-242, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38079066
4.
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Breast Cancer Res Treat;
203(2): 225-234, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37875670
5.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Breast Cancer;
30(6): 872-884, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37804479
6.
De-differentiation in cultures of organoids from luminal-type breast cancer is restored by inhibition of NOTCH signaling.
Hum Cell;
36(6): 2099-2112, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37634223
7.
Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis.
Case Rep Oncol;
16(1): 491-496, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37497420
8.
Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
Breast Cancer;
30(5): 856-868, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37422608
9.
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Breast Cancer Res Treat;
199(2): 253-263, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37000345
10.
Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy.
Jpn J Clin Oncol;
53(3): 195-202, 2023 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36702740
11.
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Acta Med Okayama;
76(6): 661-671, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36549768
12.
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
PLoS One;
17(11): e0278344, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36445924
13.
Efficacy of Telemedicine Using Videoconferencing Systems in Outpatient Care for Patients With Cancer: A Systematic Review and Meta-Analysis.
JCO Clin Cancer Inform;
6: e2200084, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36417685
14.
Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
World J Oncol;
13(4): 216-221, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36128594
15.
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
Support Care Cancer;
30(10): 8367-8375, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35857127
16.
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Breast Cancer;
29(5): 796-807, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35460066
17.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol;
23(5): 636-649, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405087
18.
Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Breast Cancer;
29(1): 186-188, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34562260
19.
Cancer patient satisfaction with health care professional communication: An international EORTC study.
Psychooncology;
31(3): 541-547, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34546631
20.
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Breast Cancer;
29(1): 131-143, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34491513